Filing Details

Accession Number:
0001104659-24-100747
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-17 19:19:17
Reporting Period:
2024-09-14
Accepted Time:
2024-09-17 19:19:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1720893 Bioxcel Therapeutics Inc. BTAI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1672718 Vincent O'neill C/O Bioxcel Therapeutics, Inc.
555 Long Wharf Drive, 12Th Floor
New Haven CT 06511
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-09-14 521 $0.00 4,045 No 4 M Direct
Common Stock Disposition 2024-09-16 138 $0.69 3,907 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-09-14 521 $0.00 521 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,127 No 4 M Direct
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
  3. On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.